Dermatitis herpetiformis (DH) merupakan penyakit kulit autoimun kronik-residif akibat proses sekunder hipersensitivitas terhadap gluten. Kejadian DH tinggi pada populasi dengan predisposisi genetik HLA-DQ2 atau DQ8. Manifestasi klinis DH berupa lesi polimorfik ruam papulo-vesikular atau papul-eskoriasi didominasi rasa gatal. Baku emas diagnosis DH adalah pada pemeriksaan DIF didapatkan deposit imunoglobulin (Ig)-A granular di stratum papila dermis. Diet bebas gluten merupakan tata laksana utama. Dapson menjadi obat pilihan pertama. Prognosis baik dengan diagnosis dan tata laksana yang tepat. Dermatitis herpetiformis (DH) is a chronic-recurrent autoimmune skin disease caused by secondary hypersensitivity to gluten. The incidence of DH is high in population with genetic predisposition to HLA-DQ2 or DQ8. Clinical manifestations of DH are polymorphic lesions, papulo-vesicular rash or papules-excoriations, dominated by itching. The gold standard for diagnosis is the presence of granular immunoglobulin (Ig)-A deposits in the stratum papilla dermis on DIF examination. A gluten-free diet is the mainstay of treatment. Dapsone is the drug of choice. Prognosis is good with proper diagnosis and treatment.

Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae) that involves the integumentary and peripheral nervous system, causing neuropathy, deformity, and disability. Early detection and appropriate treatment are the ways to break the chain of transmission and prevent disability in leprosy patients. The first line of treatment for leprosy is the standard Multidrug Therapy (MDT) regiment consisting of rifampicin, dapsone, and clofazimine. Standard MDT treatment is given based on the leprosy classification of paucibacillary (PB) and multibacillary (MB). The utilization of the standard MDT regiment has some limitations, particularly where there is a limited supporting test facility, causing difficulty in determining the leprosy classification accurately. An alternative regiment proposed to substitute the standard MDT is the Uniform-MDT (U-MDT). Several studies have been conducted on the use of U-MDT and have produced promising results for the treatment of PB and MB leprosy.

Erythroderma is a severe skin disorder that requires immediate and adequate treatment. The most common cause of erythroderma, which can be detrimental to the patient's life, is psoriasis. We describe a case of erythroderma psoriasis (EP) in a 57-year-old male patient without underlying systemic disease. The patient was diagnosed based on his medical history and physical examination. The management is interdisciplinary and comprehensive. Patients' clinical outcomes improved significantly after receiving topical and systemic corticosteroids.

<div class="WordSection1"><div class="WordSection1"><p>Pemphigus vulgaris is an autoimmune disease characterized by mucocutaneous involvement in the form of loose bullae on the skin and mucous membranes. This disorder is typically associated with the poor general condition and can be life-threatening. Furthermore, it has a rare incidence among elders. Pemphigus vulgaris was reported in a 73-year-old female patient. The diagnosis was performed clinically according to the history of the disease course and its typical lesions with a predilection for location. The patient's clinical condition improved after receiving systemic corticosteroids and additional supportivetherapy.</p></div></div>

<p class="abstract">Juvenile dermatomyositis (JDM) is a rare autoimmune disease that affects mostly children's muscles and skin. The small number of patients with JDM, heterogeneous disease phenotype, and few clinical trials for JDM pose challenges for clinicians in developing standard treatment protocols. Although there has been some consensus, the obstacles to JDM therapy, especially in refractory cases, have not been resolved. Dapsone is one of the anti-inflammatory agents that can provide significant clinical improvement in patients with dermatomyositis. This aim of the study was to discuss various previous studies to determine the potential use of dapsone in cases of refractory JDM.</p>